ELI LILLY & Co 4

Director J. Erik Fyrwald acquired about 8.65 deferred stock units of Eli Lilly & Co common stock worth roughly $1,100 as part of director compensation.

On July 20, 2026, J. Erik Fyrwald, a director of Eli Lilly & Co, acquired approximately 8.65 shares of common stock valued at about $1,147 through the Lilly Directors' Deferral Plan, electing to receive deferred stock units in lieu of cash compensation, which will be settled in shares of common stock upon his separation from service; following this routine compensation-related award, his beneficial ownership increased to roughly 75,409.74 shares, representing an estimated post-transaction holding value of about $88.5 million based on the current market price.

Filing Facts

CIK

59478

Ticker

LLY

Form

4

Source Type

fda

Accession

0000059478-26-000066

Alert Tier

4